23032-21-5Relevant articles and documents
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues
Sparks, Steven M.,Banker, Pierette,Bickett, David M.,Clancy, Daphne C.,Dickerson, Scott H.,Garrido, Dulce M.,Golden, Pamela L.,Peat, Andrew J.,Sheckler, Lauren R.,Tavares, Francis X.,Thomson, Stephen A.,Weiel, James E.
scheme or table, p. 981 - 985 (2009/08/15)
Optimization of the amino acid residue of a series of anthranilimide-based glycogen phosphorylase inhibitors is described leading to the identification of serine and threonine ether analogs. t-Butylthreonine analog 20 displayed potent in vitro inhibition of GPa, low potential for P450 inhibition, and excellent pharmacokinetic properties.
The first low molecular weight antibiotic from lactic acid bacteria: Reutericyclin, a new tetramic acid
Hoeltzel, Alexandra,Gaenzle, Michael G.,Nicholson, Graeme J.,Hammes, Walter P.,Jung, Guenther
, p. 2766 - 2768 (2007/10/03)
The first chemical proof is available to show that lactic acid bacteria, generally known for their limited metabolite spectrum, are able to produce antibiotics with a broad inhibitory spectrum. The new tetramic acid, reutericyclin (1), opens a new dimension in the discussion regarding the application of lactic acid bacteria in food preservation or for positively influencing the human intestinal microflora.
Opticar Resolution of the D- and L-Amino Acid Family by Liquid-Solid Chromatography
Dobashi, Akira,Oka, Kitaro,Hara, Shoji
, p. 7122 - 7123 (2007/10/02)
-